View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 18, 2011

Sun Pharma to Market Uroxatral Generic

Sun Pharmaceutical has received US Food and Drug Administration approval to market a generic version of Sanofi's Uroxatral tablets in the US. A Sun Pharma subsidiary has been given permission to market 10mg alfuzosin hydrochloride tablets, used to treat prostatic hyperplasia.

By cms admin

Sun Pharmaceutical has received US Food and Drug Administration approval to market a generic version of Sanofi’s Uroxatral tablets in the US.

A Sun Pharma subsidiary has been given permission to market 10mg alfuzosin hydrochloride tablets, used to treat prostatic hyperplasia.

Alfuzosin hydrochloride tablets have annual sales of approximately $250m in the US, and Sun Pharma has claimed that its version is therapeutically equivalent to Sanofi’s Uroxatral.

Sun Pharma also confirmed that it has received 180-day marketing exclusivity of the drug.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology